In my last article I summarized my discussions with DelMar Pharmaceuticals’ (Nasdaq: DMPI) President and CEO Saiid Zarrabian and the value proposition DelMar offers investors. To recap, DelMar … [Read more...] about DelMar Pharmaceuticals (Nasdaq: DMPI) Approaches a Key Inflection Point At the 2019 Society for Neuro-Oncology Annual Meeting
trading
Exclusive New Feature: MS Biotech Financial Health Score
Hello there, MS Chief Pharmaceutical Officer Chris here. I am elated to share something we have been working diligently on: an objective score to help evaluate biotechnology company. As the first of … [Read more...] about Exclusive New Feature: MS Biotech Financial Health Score
Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Foamix Pharmaceuticals (NASDAQ: FOMX) shares have been on a free fall for the past six months, declining by more than 30 percent to $2.3. The clinical-stage company which develops and commercializes … [Read more...] about Foamix Pharmaceuticals: A dermatology play with more than 100% upside potential
Immunomedics’ Risk vs. Reward
Press play on chart to watch IMMU trade in real-time. #IMMU look at Risk vs. Reward #Volatilitywatch by follow_the_money on TradingView.com Immunomedics Inc. (Nasdaq: IMMU) brings … [Read more...] about Immunomedics’ Risk vs. Reward
MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Biopharma Stock Watch July 8th-12
Source: MS Money Moves Overall it was a red week for biotech whereas the greater market (S&P, NASDAQ, and DOW) gained a little under +1% each. In the past 30-days the healthcare sector … [Read more...] about Biopharma Stock Watch July 8th-12
Biopharma Stock Watch July 1st-4th
It suffices to say Q2 2019 (April-June) has been a wild ride. In 1Q19 the market bounced back with a vengeance from its low-point in December 2018 when it appeared the U.S and China were on the cusp … [Read more...] about Biopharma Stock Watch July 1st-4th
Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
To recap, in part 1 we talked about Evolus (Nasdaq: EOLS), a relatively young company (no pun intended) entering the medical aesthetics market. Their first product Jeuveau was approved by FDA in … [Read more...] about Evolus: A Performance Beauty Company “Built to Grow Overnight”: Part 2
My #1 Mid-Cap Biotech Stock Pick For 2019
The four qualities that I assign the most weight when evaluating a biotech company for viability is 1) An efficacious product 2) Sufficient funding 3) Competent leadership and 4) Relationships with … [Read more...] about My #1 Mid-Cap Biotech Stock Pick For 2019
A Look At ADMA Biologics Investor Presentation At Jefferies 2019 Healthcare Conference
ADMA Biologics (Nasdaq: ADMA), an innovator in the manufacturing and sale of intravenous immunoglobulin (IVIG) medicine, delivered a 23 minute presentation June 6th at the Jefferies 2019 Healthcare … [Read more...] about A Look At ADMA Biologics Investor Presentation At Jefferies 2019 Healthcare Conference
You must be logged in to post a comment.